Comments
Shares of Sun Pharma Advanced Research Company (SPARC) today slumped nearly 16 per cent after the company said its pivotal studies on treatment of spasticity in patients with multiple sclerosis did not meet the desired outcome.
The stock dropped 14.72 per cent to Rs 332 on the BSE. On the NSE, it tanked 15.64 per cent to Rs 328.
Baclofen GRS is a novel, once-a-day formulation developed by the company’s proprietary gastroretentive system (GRS) technology, SPARC said in a filing to the BSE.
SPARC CEO Anil Raghavan had said: “We are disappointed with the outcomes of these studies and will evaluate the data in greater detail to decide on our next steps.”
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.